How do you treat muscle invasive bladder cancer with neuroendocrine differentiation?
How would non-regional adenopathy change management? What about poor surgical candidacy?
Answer from: Medical Oncologist at Community Practice
Ultimately, treatment would depend upon the percentage of neuroendocrine differentiation present. If it were < 50%, I would continue to treat as MIBC. This would involve neoadjuvant cisplatin-based chemotherapy if the patient were eligible followed by RC. If the patient were not cisplatin-eligibl...
Sign in or Register to read more